How can our governments and health officials allow crooked companies like this to provide drugs and vaccines to our children?

To ghostwrite an entire textbook is a new level of chutzpah. I’ve never heard of that before. It takes your breath away.” said Dr. David A. Kessler, former commissioner of the Food and Drug Administration, speaking to the New York Times after reviewing the documents:

“Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say” By Duff Wilson THE NEW YORK TIMES – November 29, 2010.

We republish here a 30 November 2010 edited article from Vera Hassner Sharav of the New York charity Alliance For Human Research Protection – reporting on the story from The New York Times about GSK’s drug pushing psychiatry book.

But first some important related history we can safely and legally describe as what a number of money grabbing drug pushing crooks were also caught doing in the then named SmithKline Beecham corporation. GSK was prosecuted in a fraud case by New York USA Attorney General Elliott Spitzer in June 2004 over its “deceptive, fraudulent and unlawful practices” in drug pushing to children its “anti-depressant” drug Paxil [called Seroxat in the UK]: NY Supreme Court Complaint by NY AG Elliott Spitzer.pdf – 2 June 2004 .

WATCH THE VIDEO AND/OR READ THE STORY BELOW

GSK withheld five of six scientific studies showing that Paxil/seroxat was ineffective in use in children and it also increased the risk of suicide, self-harm and homicidal tendencies by three times. GSK published only the favourable study and actively suppressed the information of harm to children whilst pushing the drug for use in adolescents.

This class of drugs [SSRI’s or selective serotonin uptake inhibitors] now carry warnings that they cause “anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania, and mania” and have been associated with a number of murders by previously non violent individuals. [Infamous cases include Tobin v SmithKline Beecham Pharmaceuticals:

With a prior history of a poor response to an SSRI, Don Schell was put on Paxil. Forty-eight hours later he put three bullets from two different guns through his wife, Rita’s, head, as well as through his daughter, Deborah’s, head and through his granddaughter, Alyssa’s, head before shooting himself through the head.”

From chapter 10 of “Let Them Eat Prozac” By Professor David Healy, North Wales Department of Psychological Medicine, Pub: James Lorimer for the Canadian Association of University Teachers, ISBN no 1-55028-783-4]

But the GlaxoSmithKline company was not deterred from suppressing the risk information to children and withholding it from doctors to make sales whilst literally putting childrens’ lives and the lives of those around them at risk.

Should we trust those “awfully nice” British Glaxo people?

The UK’s Independent reported in July 2004:-

“A new warning that the controversial antidepressant Seroxat may increase the risk of suicide in young adults up to the age of 30 is to be issued throughout Europe.“

A letter of complaint, by the Project on Government Oversight (POGO) was sent to the director of the National Institutes of Health (below), documenting $66.8 million in NIH grants that were awarded to a handful of psychiatrists who penned their name to ghostwritten scientific publications [see full text of letter and references below].

The instances identified in the letter involve ghostwriting by only one company–Scientific Therapeutics Information–and only one drug–GlaxoSmithKline’s antidepressant, Paxil (peroxetine).

Duff Wilson of The New York Times reports that previously sealed GlaxoSmithKline documents show that a psychiatry textbook, whose listed authors are psychiatrists, Charles Nemeroff, MD and Alan Schatzberg, MD, was actually ghostwritten by Sally Laden of STI. GSK paid the ghostwriter and the “authors” who penned their names to the book.

But then, psychiatry and its leadership has the notorious distinction of lacking a minimal scientific foundation to support just about any of its clinical practice guidelines–as the entire field is driven not by honest research, but by the financial interests of the pharmaceutical industry and their paid “partners” in academia.

Drs. Nemeroff and Schatzberg are two of psychiatry’s influential academics who have received tens of million dollars in taxpayer grants, who have chaired departments of psychiatry at Emory University, the University of Miami (CN) and Stanford University (AS).

The POGO letter of complaint is accompanied by a “smoking gun”–a 1997 letter written by the book ghostwriter:

“A draft of the textbook states that it was sponsored by GSK and written by Diane M. Coniglio and Sally K. Laden of STI. (Attachment D ) In a letter addressed to Dr. Nemeroff, Ms. Laden provided an updated status of the textbook. Her timeline states that she wrote the first draft, which was then sent to Drs. Nemeroff and Schatzberg, the publisher, and GlaxoSmithKline. The timeline also notes that GSK was given all three drafts, and was sent page proofs for final approval. (Attachment E)”

Drs. Nemeroff and Schatzberg insist that the the company’s grant was “unrestricted” and, therefore, they claim to have done “most of the work.”

Duff Wilson reports that Dr. Nemeroff defends the book, stating it “was written to fill an unmet need in educating family doctors and primary care physicians on how to provide adequate treatment for people with mental illness.”

Ghostwritten articles and ghostwritten texbooks paid for and controlled by self-serving drug companies have undermined the integrity of science and pose a threat to public health!!

Pity the people whose doctors’ clinical practice is guided by fraud.

Below, we post a copy of the POGO letter to the director of NIH–in which a handful of researchers who used ghostwriters for scientific publications are identified. These prominent academic psychiatrists received $66.8 million in NIH grants over the last five years.

Shouldn’t anyone who engages in professional misconduct such as fraud, which corrupts the integrity and practice of medicine, be disqualified from having academic standing?

POGO Letter to NIH on Ghostwriting Academics

Via email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Dear Dr. Collins:

The Project On Government Oversight (POGO) is a nonpartisan independent watchdog that champions good government reforms. POGO’s investigations into corruption, misconduct, and conflicts of interest achieve a more effective, accountable, open, and ethical federal government. We take a keen interest in strengthening the integrity of federally funded science, and have particular concerns involving the National Institutes of Health (NIH), which receives around $30 billion a year in federal taxpayer dollars to fund biomedical research.[1]

We are writing to urge that NIH curb the practice of ghostwriting in academia. As the Director of the world’s largest and most prestigious funding source for biomedical research, you must set policies that require NIH-funded academic centers to ban ghostwriting to strengthen scientific integrity.

You obviously recognize how corrosive ghostwriting is to science. In an interview last year on C-SPAN, you said:

I was shocked by that revelation—that people would allow their names to be used on articles they did not write, that were written for them, particularly by companies that have something to gain by the way the data is presented….If we want to have the integrity of science preserved, that’s not the way to do it.[2]

We couldn’t agree more, and would think NIH policies would prevent such practices. However, based on documents in our possession, we have discovered that the NIH gave $66.8 million in grants over the last five years to a handful of researchers who used ghostwriters for scientific publications. These documents were made public during litigation[3] about Paxil (paroxetine), an anti-depressant sold by GlaxoSmithKline (GSK). Although these documents discuss actions that happened in the past, this behavior doesn’t usually come to light until years after it occurred when the evidence is discovered during litigation, and therefore the practice is likely continuing today.

According to the documents, GSK began to push sales of Paxil in the early 1990s with an extensive ghostwriting program run by the marketing firm Scientific Therapeutics Information (STI). For instance, STI wrote a proposal to organize GlaxoSmithKline’s Paxil Advisory Board Meeting in 1993 at the Ritz Carlton Hotel in Palm Beach, Florida. STI chose Dr. Charles Nemeroff of Emory University as their speaker to lay out the meeting’s agenda and objectives. Dr. Nemeroff apparently led discussions on how to “evaluate clinical research/promotional programs” and “generate information for use in promotion/education.” (Attachment A)

STI’s ghostwriting included editorials, journal articles, and even a textbook that was widely used by primary care physicians to treat psychiatric disorders. Below are further details of these incidents and the NIH funding of these researchers.

According to the documents, Sally Laden of STI wrote an editorial for Biological Psychiatry in 2003 for Drs. Dwight Evans, Chairman of the Department of Psychiatry at the University of Pennsylvania School of Medicine, and Dennis Charney, then an employee at the NIH and now Dean of Research at the Mt. Sinai School of Medicine at New York University.[4]

In an email to a GSK employee, Ms. Laden wrote, “Is there a problem with my invoice for writing Dwight Evans’ editorial for the [Depression and Bipolar Support Alliance]’s comorbidity issue to Biological Psychiatry?” (Attachment B) Yet, when published, the “authors” Evans and Charney only stated, “We acknowledge Sally K. Laden for editorial support.” (Attachment C)

According to the NIH Reporter database of grants, Dr. Evans is the primary investigator on two NIH grants. The funding for these grants in 2010 is $940,450. Dr. Charney is the primary investigator on one NIH grant, whose funding in 2010 is $9,989,340. Over the last five years, the NIH has given both researchers $30.6 million in grants.[5]

STI also ghostwrote a physician textbook, Recognition and Treatment of Psychiatric Disorders, for Drs. Alan Schatzberg of Stanford Medical Center and Charles Nemeroff, formerly with Emory University School of Medicine and now at University of Miami School of Medicine.

A draft of the textbook states that it was sponsored by GSK and written by Diane M. Coniglio and Sally K. Laden of STI. (Attachment D) In a letter addressed to Dr. Nemeroff, Ms. Laden provided an updated status of the textbook. Her timeline states that she wrote the first draft, which was then sent to Drs. Nemeroff and Schatzberg, the publisher, and GlaxoSmithKline. The timeline also notes that GSK was given all three drafts, and was sent page proofs for final approval. (Attachment E)

However, in the textbook’s published preface, Dr. Nemeroff and Schatzberg only thank STI for “editorial assistance” and GSK for “providing an unrestricted educational grant.” (Attachment F)

The fact that STI wrote the first draft undermines Drs. Nemeroff and Schatzberg’s assertion that STI provided mere “editorial assistance.” Also, GSK’s involvement in every draft, to include sign-off of page proofs, undermines the assertion that the company’s grant was “unrestricted.”

According to the NIH Reporter database of grants, Dr. Schatzberg is the primary investigator on four NIH grants. The funding for these grants in 2010 is $2,374,242. Over the last five years, the NIH has given both researchers $23.3 million in grants.[6]

In 2002, a GSK employee emailed Dr. Yonkers of Yale School of Medicine, writing, “Attached please find the poster to be presented at the US Psych Congress. Please provide feedback.” (Attachment G)

Other documents make it clear that Dr. Yonkers was provided at least one ghostwritten study. For instance, the cover page for a study on Paxil to be published in Psychopharmacology Bulletin notes that “Draft I” was prepared by Sally Laden and another STI employee. The top line of the draft even reminds Dr. Yonkers to remove evidence of STI’s involvement, stating, “STI Cover Page—To be removed before submission.” (Attachment H)

When the study was later published, it notes that it was funded by an “unrestricted educational grant” from GSK, but makes no mention of STI’s involvement in the paper. (Attachment I)

According to the NIH Reporter database of grants, Dr. Yonkers is the primary investigator on three NIH grants. The funding for these grants in 2010 is $1,241,257. Over the last five years, the NIH has given Dr. Yonkers $6.4 million in grants.[7]

Finally, we would like to turn your attention to Dr. Martin Keller of Brown University Medical School. In July 2001, Dr. Keller and several colleagues published a widely read study, called Study 329, on the efficacy of Paxil (paroxetine) to treat adolescent major depression.[8] Study 329 concluded, “The findings of this study provide evidence of the efficacy and safety of the SSRI, paroxetine, in the treatment of adolescent major depression.”[9]

Study 329, however, was clearly flawed—a mere two years later, the United Kingdom government warned British physicians to not prescribe Paxil for children due to fears of potential suicide.[10] In May 2004, our own FDA issued a similar warning.[11]

In early 2007, the BBC’s investigative program Panorama released a documentary on Paxil and Study 329.[12] The documentary publicized hundreds of secret emails from GSK, which were uncovered during litigation, that showed GSK knew years before the publication of Study 329 that Paxil did not provide efficacy in treating adolescents for depression.

With regards to Study 329 specifically, the BBC reported online about emails written by a company hired by GSK to provide PR for Study 329.[13] One email read, “Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results.”[14] Another email read, “Essentially the study did not really show [Paxil] was effective in treating adolescent depression, which is not something we want to publicize.”[15] (Attachment J)

The documentary also noted that Dr. Keller published Study 329 with the help of ghostwriter Sally Laden. In an email to Ms. Laden about Study 329, Dr. Keller wrote, “You did a superb job with this. Thank you very much. It is excellent. Enclosed are some rather minor changes from me…”[16] But before the final draft was released to Dr. Keller, Ms. Laden sent it to GSK for final approval so that the manuscript “can be released to Martin Keller, MD to submit for publication….” (Attachment K)

In June 2008, former Boston Globe reporter Alison Bass published Side Effects, a book that documents multiple problems with Dr. Keller’s research used in Study 329. Passages of the book discuss internal documents from Brown University regarding Dr. Keller’s research on Paxil. The documents were provided to Ms. Bass by Donna Howard, the former assistant administrator in Brown’s department of psychiatry. Ms. Howard said that data in Study 329 was changed to satisfy the study’s sponsor, GSK. According to Howard, “Everybody knew we had to keep [GlaxoSmithKline] happy and give them the results they wanted.”[17]

Even Brown University’s student newspaper, The Brown Daily Herald, published an exposé on Dr. Keller’s research and Study 329.[18] Dr. Keller refused to respond to questions from the paper. An editorial that accompanied this story stated, “We do believe that [Dr. Keller’s] actions directly affect the integrity of the University.”[19] Yet, despite the multiple public revelations, Brown University has done nothing.

POGO searched the NIH Reporter database of grants and was surprised to find that, despite all the repetitive controversy, Dr. Keller is still receiving NIH grants. Currently, he is the primary investigator on two NIH grants, with funding in 2010 of $1,341,493. Over the last five years, the NIH has given Dr. Keller $7 million in grants.[20]

Conclusion

The instances in this letter involve ghostwriting by only one company and involve only one drug. Yet the evidence is that this practice is widespread and pervasive in academia. A study published in PLoS Medicine in February of this year found that only ten of the top fifty medical schools explicitly prohibit ghostwriting.[21] The study’s authors concluded that “medical ghostwriting is a threat to public health….”[22]

NIH must take a firm stance against ghostwriting, both to protect public health and the integrity of NIH funding. We ask that you implement new policies that will require institutions to ban ghostwriting, and to make NIH funding contingent upon periodic certification from institutions that ghostwriting is strictly prohibited and that enforcement mechanisms such as disciplinary action and dismissal are in place. Setting this example will improve the integrity of federally funded science. Additionally we ask that you fund seminars and research on ghostwriting to educate physicians about this practice and ensure that it disappears from biomedical research altogether.

We appreciate your review of this letter and your time, and look forward to working with you on the issue of ghostwriting in academia. If you have any questions, please do not hesitate to contact Paul Thacker at (202) 347-1122 or This e-mail address is being protected from spam bots, you need JavaScript enabled to view it